Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a histologic or cytologic diagnosis of stage III/IV ovarian cancer, fallopian tube epithelial cancer, or peritoneal cancer who have not received prior chemotherapy or radiotherapy.~* Subjects must have the appropriate surgery for their gynecologic cancer. However, subjects may be treated in a neoadjuvant manner, with surgery being performed after chemotherapy cycles 1, 2, or 3.~* If neoadjuvant therapy is not administered, subjects must receive their first dose no more than six weeks postoperatively.~* Subjects must have adequate bone marrow, renal and hepatic function as defined by WBC \> 3,000 cells/cu ml., platelets \> 100,000/cu.ml., calculated creatinine clearance \> 50 ccs/min., bilirubin \< 1.5 mg/dl, and SGOT \< three times normal.~* Karnofsky performance status \> 50%.~* Subjects who have signed an institutional review board (IRB) approved informed consent form.~Exclusion Criteria:~* Subjects with epithelial ovarian cancer of low malignancy potential.~* Subjects with septicemia, severe infection, or acute hepatitis.~* Subjects with a history of congestive heart failure, angina, or a history of myocardial infarction within the past six months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat (Type: EXPERIMENTAL): All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).